Last updated on July 2020

A Study of Zolbetuximab (IMAB362) Plus CAPOX Compared With Placebo Plus CAPOX as First-line Treatment of Subjects With Claudin (CLDN) 18.2-Positive HER2-Negative Locally Advanced Unresectable or Metastatic Gastric or Gastroesophageal Junction (GEJ) Adenocarcinoma


Find a site near you

Start Over

Site AR54008

Córdoba, Argentina
  Connect »

Site AR54008

Córdoba, Argentina
  Connect »

Site AR54008

Córdoba, Argentina
  Connect »

Site AR54008

Córdoba, Argentina
  Connect »

Recruitment Status: Open


Brief Description Eligibility Contact Research Team


Volunteer Sign-up

Sign up for our FREE service to receive email notifications when clinical trials are posted in the medical category of interest to you.